Considering our observations in ERα-positive early breast cancer patients, it is not likely that PIK3CA hotspot mutation status by itself would be a suitable companion diagnostic predicting benefit from the putative use of PI3K/AKT/mTOR inhibitors in the adjuvant setting. This evidence concerns the gene PIK3CA and breast cancer.